A routine Institutional Review Board (IRB) audit discovered that full consent was not obtained from 21 of the 44 patients included in the study; consent specifically for access to unidentifiable clinical information from the patients' medical records had not been obtained. This error was due to a miscommunication between the researchers conducting the study and the surgeons who had obtained consent.
Introduction
The renin-angiotensin system (RAS) plays a crucial role in the regulation of blood pressure and fluid balance, while in the heart increased angiotensin II (Ang II) expression and activity contributes to adverse myocardial remodeling, collagen deposition and arrhythmias. Although increased cardiac expression of RAS components are linked to the pathogenesis of heart disease, the outcomes of trials evaluating the efficacy of angiotensin converting enzyme (ACE) inhibitors, Ang II receptor blockers (ARBs) or a direct renin inhibitor have not fully achieved the benefits that would be expected from a robust experimental literature documenting Ang II as a cause of or a major contributor to the pathogenesis of heart disease [Disertori et al. 2012; Laight, 2009; Turnbull et al. 2005 Turnbull et al. , 2007 Turnbull et al. , 2008 . To reconcile the gap between treatment effects in animal experiments and clinical trials results, proposed explanations include species differences in Ang II processing pathways in humans and animals [Balcells et al. 1997; Ferrario et al. 2005b] , compensatory ACE inhibition escape [Ennezat et al. 2000; van den Meiracker et al. 1992] , failure of drugs to access the intracellular sites at which Ang II acts [Baker et al. 1992; De Mello and Danser, 2000; Dostal and Baker, 1999; Kumar et al. 2012] , or these factors in combination. A new perspective to this problem emanates from the identification of an alternate tissue Ang II forming mechanism in which an endogenously produced extended form of angiotensin I (Ang I) liberates Ang II directly through a nonrenin pathway [Nagata et al. 2006; Trask et al. 2008 ].
Angiotensin-(1-12) ], a newly identified peptide from rat small intestine is expressed in the heart and kidneys of rats at concentrations much higher than those of Ang I and Ang II [Nagata et al. 2006 ]. Through a series of publications we showed: (1) increased expression and content of Ang-(1-12) in the hypertrophied heart of spontaneously hypertensive rats (SHR)  (2) the production of Ang II from Ang-(1-12) to be independent of renin in the isolated heart of two rat hypertensive strains and three normotensive control rats , the heart of anephric Wisto-Kyoto (WKY) rats [Ferrario et al. 2009 ] and rats fed a low salt diet [Nagata et al. 2010] ; and (3) a contribution of chymase in Ang-(1-12) metabolism in the heart of SHR [Ahmad et al. 2011b ] while ACE accounts for the degradation of Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) in the circulation of both WKY and SHR . In extending these experimental findings to the human heart we identified Ang-(1-12) and chymase in left atria specimens from patients undergoing heart surgery [Ahmad et al. 2011a ] and left ventricle of normal subjects ].
The significant differential roles of ACE and chymase in Ang-(1-12) metabolism between rats and human heart tissue coupled with our demonstration of co-expression of Ang-(1-12) with chymase [Ahmad et al. 2011a] suggested that this alternate substrate for Ang II production, being cleaved by chymase rather than ACE, may contribute to the pathogenesis of arrhythmias and the structural cardiac remodeling associated with diseases of the left heart. Since activation of autonomic nervous system mechanisms contribute to heart disease pathogenesis and particularly atrial fibrillation (AF) [Linz et al. 2014] , we also explored relations among atrial Ang-(1-12), chymase activity, brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and gene expression of tyrosine hydroxylase (TH) and neuropeptide Y (NPY) as markers of cardiac sympathetic neurotransmission in right atrial appendage (RAA) and left atrial appendage (LAA) specimens from patients undergoing heart surgery.
Methods

Ethical statement
The study was approved by the Wake Forest University Medical Center (IRB 22619). Atrial appendages were obtained from 44 patients undergoing cardiac surgery at the Wake Forest University Baptist Medical Center (Winston-Salem, NC, USA). Left and right segments of the atrial appendages were resected during cardiopulmonary bypass for correction of left cardiac valve replacement [aortic valve replacement (AVR), mitral valve regurgitation (MVR)], treatment of resistant AF using the MAZE procedure [Cox et al. 1993] , or coronary artery bypass grafting (CABG) ( Table 1) . Medical history, medications and specific surgical indication are documented in Table 1 . Preoperative transthoracic echocardiograms (Table 2) and consent forms were obtained prior to cardiac surgery.
Ang-(1-12) immunohistochemistry:
Human angiotensin-(1-12) was synthetized for us by AnaSpec Inc. (San Jose, CA). Immunohistochemistry was performed using an affinity purified polyclonal antibody directed to the COOHterminus of the full length of the sequence of human Ang-(1-12) (Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 -Phe 8 -His 9 -Leu 10 -Val 11 -Ile 12 ). In prior studies we documented that this human Ang-(1-12) antibody does not crossreact with either Ang I or Ang II [Ahmad et al. 2011a . Excised segments of the LAA and RAA were immediately immersed in a solution of 4% paraformaldehyde for 24 hours and then transferred into 70% ethanol. After dehydration, the tissues were embedded in paraffin and cut into 5 micron thick sections. Slides were warmed for 1 hour (55°C), deparaffinized in xylene and, after being subsequently dipped in serial solutions of ethanol (100%, 95%, 85% and 70%), were rinsed in phosphate buffered saline (PBS). The slides were incubated in an antigen retrieval buffer (Antigen Unmasking Solution H-3300; Vector Laboratories Inc., Burlington, CA) and washed with double distilled water. Slides were then incubated for 5 min in 3% hydrogen peroxide to block the endogenous peroxidase. The sections were blocked with 1% bovine serum in PBS with 5% normal goat serum for 1 hour at room temperature and then incubated with the affinity-purified human Ang-(1-12) primary antibody (1:1000 dilution in 1% BS in PBS with 5% normal goat serum) overnight at 4°C. Sections independently treated with 5% normal goat serum in the absence of the primary antibody served as negative controls. Additional controls included sections treated with the primary antibody preincubated with a 20-fold excess of human Ang-(1-12) peptide. After incubating with the primary antibody, each section was washed three times in PBS. The sections were blocked with 1% BS in PBS with 5% normal goat serum for 1 hour at room temperature and then incubated with biotinylated goat antirabbit secondary antibody (1:400 dilutions in 1% BS in PBS with 5% normal goat serum; Vector Laboratories Inc., Burlington, CA) for 3 hours. After washing the secondary antibody with PBS, sections were stained with 3,3′-diaminobenzidine (DAB, Sigma-Aldrich Chemical Co. St. Louis, MO) in Tris-buffered saline (0.05 mol/l, pH 7.65), and counterstained with hematoxylin before being dehydrated and mounted. The Ang-(1-12) staining-positive rates were calculated using Image J software (http://imagej.nih.gov/ ij/), a public domain Java image processing program developed by the US National Institutes of Health.
Chymase activity assay
Native plasma membranes (PMs) were prepared as described previously [Ahmad et al. 2011a . The frozen atrial tissues (30-60 mg) were (200g) for 1 min at 4°C to remove the connective tissue and cell debris. The supernatant was transferred into a new tube and centrifuged at 28,000g for 20 min at 4°C. The pellet (native membranes) was resuspended in the reaction buffer and stored at -80°C until assayed for chymase activity.
125 I-Ang-(1-12) metabolism by human atrial tissue PMs were studied in the absence or presence of the chymase inhibitor chymostatin (Figure 1 ). Highly purified human 125 I-Ang-(1-12) substrate [1 nmol/l of 125 I-Ang-(1-12)] was added to native Results are representative of three or more separate metabolism experiments in the human samples. 
Analysis of gene expression by quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (PCR) was used to detect gene mRNA levels in human atrial tissue. Total RNA was extracted from frozen, pulverized atria using TRIzol Reagent and processed according to the manufacturer's recommendations. The quality and quantity of RNA samples were determined by spectrometry and agarose gel electrophoresis. Complementary first strand DNA was synthesized from oligo (dT)-primed total RNA, using the Omniscript RT kit (Qiagen Inc., CA). Relative quantification of mRNA levels by real-time PCR was performed using a SYBR Green PCR kit (Qiagen Inc., CA). Amplification and detection were performed with the ABI7500 Sequence Detection System (Applied Biosystems). Only one peak from the dissociation curve was found from each pair of oligonucleotide primers tested. Real-time PCR was carried out in duplicate; a notemplate control was included in each run to check for contamination. It was also confirmed that no amplification occurred when samples were not subjected to reverse transcription. Sequence-specific oligonucleotide primers were designed according to published GenBank sequences (www.ncbi.nlm.nih.gov/Genbank) and confirmed with Oligo-Analyzer 3.0 ( Table 3) . The relative target mRNA levels in each sample were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Echocardiography
Preoperative echocardiograms were read by highly trained cardiac sonographers using a 1-5 MHz phased array transducer (Philips S5-1) and Philips iE33 sector scanner (Philips Medical Systems, Andover, MA). Digitally stored images were reviewed and final reports were completed offline (Xcelera 3.1; Koninklijke Philips Electronics, Amsterdam, The Netherlands) by cardiologists board certified in adult echocardiography. The preoperative transthoracic echocardiograms reported here were the studies most proximate to the patient's surgery. An experienced investigator trained in perioperative echocardiography (L.G.), who was masked to biochemical and histological findings, manually reviewed all stored images in conjunction with the archived echocardiographic report. Transthoracic echocardiograms were performed and analyzed according to American Society of Echocardiography recommendations [Lang et al. 2005] . Left ventricular end-diastolic and end-systolic internal diameters (LVID and LVIS, respectively), end-diastolic LV posterior wall (LVPW) and interventricular septal diameters (IVS), and left ventricular end-systolic left atrial diameter measurements were acquired and measured from the parasternal long-axis view using two-dimensional guided M-mode echocardiography by the leading edge-to-leading edge technique. Left ventricular end-diastolic and end-systolic volumes (EDV and ESV, respectively) and left atrial (LA) volume at end ventricular systole were measured by the biplane method of disks (modified Simpson's rule) using apical 4-chamber and apical 2-chamber view. Left ventricular ejection fraction (LVEF) was calculated as LVEF (%) = [(EDV-ESV/EDV)] × 100 %. Mitral inflow measurements of early and late filling velocities were obtained using
pulsed Doppler, with the sample volume placed at the tips of mitral leaflets from an apical fourchamber orientation. The early-to-late filing velocity ratio (E/A) was calculated in those patients who were in sinus rhythm at the time of the examination.
Statistics
All results are presented as mean ± standard error (SE). Statistical analysis was carried out using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). Differences between LAA and RAA were evaluated using Student's t-test for unpaired values. Analysis of variance (one-way ANOVA) followed by Bonferroni's multiple comparison test was employed in evaluating differences among echocardiographic variables. Pearson's correlation coefficient was used for analyzing associations among molecular, biochemical and clinical characteristics. Values of p < 0.05 were considered significant.
Results
A total of 51 RAA and LAA specimens were obtained from 44 subjects, who were predominately male and older than 60 years of age (Table  1) . Approximately the same numbers of RAA and LAA specimens were obtained from subjects undergoing cardiac surgery (Table 1) . Among the examined tissues, 11 specimens were obtained from patients in whom the surgical intervention was associated with placement of incisions within the atrial tissue to block the conduction of errant electrical impulses for correction of atrial fibrillation [Cox et al. 1993] . Medical history and prior medications were not different between the subjects from whom RAA and LAA samples were obtained (Table 1) . Table 2 documents the state of cardiac function prior to surgical intervention. Mean LVEF was preserved across all groups of patients, although it tended to be lower in patients undergoing a CABG procedure. As expected, patients with MVR had enlarged left atriums; the left atria diameter in MVR subjects reached statistical significance when compared with those patients undergoing CABG surgery (Table 2) . Highest values of LVPW diameter were present in subjects with aortic valve disease.
Ang-(1-12) staining was visualized within the LAA and RAA tissues in all patients. The immunoreactive staining was primarily concentrated in the cytoplasm of cardiac myocytes ( Figure 2B ). There were striking differences between the Ang-(1-12) staining patterns between the left ( Figure  2B , top) and RAA ( Figure 2B , bottom) with a consistently higher expression of the peptide in the LAA. Quantitative analysis revealed 54% higher Ang-(1-12) intensity expression in the LAA compared with the RAA (Figure 3) . The differences in staining between the two cardiac chambers were further validated in seven subjects 
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in whom tissue from both their RAA and LAA were obtained (Figure 3) .
The increased Ang-(1-12) expression in the LAA was associated with higher values of chymase activity averaging 41% above those measured in RAA tissue (Figure 4) . Similarly, tissue chymase gene expression was significantly augmented in the LAA compared with the RAA (Figure 4) . The selectivity of the increases in LAA Ang-(1-12) expression, chymase mRNA and enzyme activity was further confirmed by showing that tissue expression of Aogen gene transcripts were not different in the LAA and RAA (Figure 4) . Likewise, expression of TH, BNP and ANP mRNAs were not different between the two atria (data not shown). In contrast, expression of NPY in LAA was 36% lower than the corresponding values found in the RAA (Figure 4) . Figure 5 documents that atrial expression of Aogen mRNA correlated with chymase activity and TH mRNA while NPY mRNA correlated with both Aogen and TH mRNAs. However, neither atrial Ang-(1-12) intensity nor chymase gene expression or activity correlated with patients' gender or medications.
Discussion
Little is known about the expression of angiotensin peptides in human heart disease, and no agreement exists as to whether cardiac intracrine Ang II production in humans follows biotransformation pathways identical to those described in rodents. In the pursuit of this objective, we show robust differences in the expression of Ang-(1-12) and chymase in the atrial appendages of patients with heart disease and preserved LV function. The high Ang-(1-12) expression in the LAA was associated with similar augmentation of the chymase gene and the enzymatic activity of its protein. The importance of these findings is that the increased expression and activity of this Ang II-forming pathway within atrial myocytes may not be amenable to blockade with ACE inhibitors or type 1 Ang II (AT1) receptor blockers as these drugs do not reach intracellular compartments [Kumar et al. 2012] .
Stretch is a potent stimulus for cardiac Ang II production and release [Yang et al. 1997 ]. The higher Ang-(1-12) expression and chymase activity found in the LAA of patients with valvular disease is in keeping with the observation that stretch is associated with activation of local Ang II activity [Cingolani et al. 2013 ]. In addition, increased local 
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Ang-(1-12) synthesis or myocyte uptake may be modulated by the characteristically heightened sympathetic activity found in left heart disease [Kienzle et al. 1992; Malliani and Montano, 2004; Mehta et al. 2003; Schomig et al. 1991] . Since Ang II stimulates presynaptic norepinephrine release, we suggest that stretch-induced activation of the chymase/Ang-(1-12) axis may be a linking mechanism by which Ang II facilitates increased net cardiac neurogenic drive. Moreover, increased cardiac sympathetic drives associated with volume overload causes mast cell degranulation and the attending release of chymase [Arizono et al. 1990; Melendez et al. 2011; Ries and Fuder, 1994] . Migration of mast cell-derived chymase from the cardiac interstitium into myocytes has been documented by us in patients with mitral valve insufficiency [Ferrario et al. 2014] . Patients with MVR show increased norepinephrine release rates into the extravascular compartment [Mehta et al. 2000 [Mehta et al. , 2003 , while sympathetic overactivity contributes to the pathogenesis of AF [Linz et al. 2014] . Therefore, the higher values of LAA Ang-(1-12) expression, chymase mRNA and activity may be related to the combined effects of the increased load imposed on the left atrium by either mitral valve incompetency or aortic valve restriction and increased cardiac sympathetic stimulation.
NPY is a major norepinephrine cotransmitter in postganglionic sympathetic nerves and cardiac intrinsic neurons [Kuncova et al. 2005; Pardini et al. 1992 ]. NPY gene expression was augmented in the RAA of patients with left heart disease, and the increased NPY gene expression correlated with both atrial gene expression of Aogen and the catecholamine-synthesizing enzyme TH. These data suggest that cardiac sympathetic drive may modulate the expression of cardiac Aogen as proposed in Figure 6 , possibly through a previously unrecognized activation of the Bainbridge reflex [Bainbridge, 1915] brought up by a chronic increase in cardiac preload. As defined by Bainbridge [Bainbridge, 1915] an increase in inflow to the heart produces tachycardia, a compensatory response to augment the translocation of blood through the left side heart chambers. According to Crystal and Salem [Crystal and Salem, 2012] , the characteristic increase in heart rate secondary to an increase in central blood volume is generally obtunded in humans by the more prominent action of the sinoaortic baroreceptors. Nevertheless, it is logical to assume that in conditions of a sustained increase in the central blood volume due to insufficient performance of the mitral or aortic valves, a compensatory increase in sympathetic nerve activity may help to prevent pulmonary congestion. Figure 6 outlines the mechanisms by which an increased cardiac sympathetic drive may stimulate a plastic response of the intracrine RAS resulting in activation of chymase, increased Ang-(1-12) content and consequent Ang II production ( Figure 6) .
A differential Ang-(1-12) expression between the RAA and LAA was confirmed in seven subjects in whom specimens were obtained from both atria. Increased expression of the Ang-(1-12)/chymase axis in human left heart disease is in keeping with experimental findings showing that chymase mediates the majority of Ang II production in the human heart [Balcells et al. 1997; Dell'italia and Husain, 2002] , while chymase inhibition attenuated Ang-(1-12)-induced cardiac damage following ischemia-perfusion [Prosser et al. 2009 ]. p = 0.0036 p = 0.0125 
Chymase is also an important Ang II forming mechanism within cardiomyocytes and fibroblasts [Re and Cook, 2011; Singh et al. 2008] . Moreover, the present findings extend our previous demonstration of chymase within LAA myocytes of humans with enlarged left atria undergoing the Cox-MAZE procedure for AF and the presence of chymase in left atrial myocytes of subjects with MVR [Ferrario et al. 2014] . As described elsewhere by us for the assessment of ACE2 [Ferrario et al. 2005a ] and chymase activities [Ahmad et al. 2011a [Ahmad et al. , 2011b , the chymase assay employed in these experiments obviated the use of synthetic substrates by evaluating the hydrolytic activity of the PM from the atrial tissue on 125 I-Ang-(1-12).
The human heart may not be the only site at which Ang II is generated from this noncanonical pathway. Increased chymase expression has been reported in the kidney of patients with diabetes nephropathy [Huang et al. 2003; Ritz, 2003] , the juxtamedullary afferent arteriole of diabetic mice [Park et al. 2013] , renal tissue of ACE-knockout mice [Wei et al. 2002] , and in the clipped kidney of two-kidney one clip hypertensive dogs [Tokuyama et al. 2002] .
The increased expression and activity of this Ang II-forming pathway, upstream of Ang I, did not correlate with medications. However, Aogen mRNA correlated inversely with chymase activity and positively with the expression of TH and NPY gene transcripts. The negative correlation between chymase activity and Aogen mRNA suggests, but obviously does not prove, the possibility that Aogen or a product of this substrate cleaved by chymase may negatively feedback on chymase activity.
Since most patients undergoing CABG had concomitant valvular disease, it remains to be established whether increased Ang-(1-12) expression and chymase activity would be present in subjects with a pure form of coronary artery disease. A limitation of the current study is that tissue from normal LAA/RAA was not available for comparison. However, chymase activity measured in 4 RAA tissues obtained from subjects without heart disease (unpublished observations) averaged 6.93 ± 1.66 fmol/mg/min, a value 5.3-fold lower than the corresponding RAA chymase activity found in our disease population (Figure 4) . The large difference in RAA chymase activity in normal and left-heart disease subjects reiterates the significant role of this pathway in the pathogeneses of heart disease. The proportionally higher LAA Ang-(1-12) expression and chymase activity among the group studied support the contention that both myocyte stretch and increased sympathetic drive may be operating synergistically, as both are an intrinsic mechanism for maintaining cardiac contractility. While a final answer to this possibility remains to be investigated, the data obtained in our studies provide a novel mechanism in support of the known interactions between the renin angiotensin and sympathetic nervous systems.
Differences in the distribution of cardiac regulatory peptides were reported by Onuoha and colleagues [Onuoha et al. 1999] , who showed the highest concentrations of ANP in the human right atria while the levels of calcitonin gene-related peptide (CGRP) were comparable in both atrial cavities. Species differences in the expression of cardiac peptides are also documented since the higher expression of NPY immunoreactivity in the LAA of rats, rabbits and guinea pigs was not found in human atria [Onuoha et al. 1999] . A detailed analysis of the differential expression of genome array analyses on freshly frozen atrial tissue from mice and humans identified 77 genes with preferential expression in one atrium [Kahr et al. 2011 ]. Kahr and colleagues suggest that the differential gene expression between right and left atria is a product of embryonic patterning [Kahr et al. 2011 ].
In the present study, we now demonstrate that the presence of comparable Aogen mRNA gene expression in the RAA and LAA of diseased hearts was associated with lower values of RAA Figure 6 . Diagrammatic pathways for Ang-(1-12)/ chymase system interaction with sympathetic nervous system drive to the heart.
Ang, angiotensin; ANP, atrial natriuretic peptide; AT 1 , type 1 angiotensin II; NE, norepinephrine; NPY, neuropeptide Y.
gene expression and activity of chymase and higher NPY mRNA expression. The demonstration of a differential expression of Ang-(1-12) and chymase mRNA and activity between the two atria appendages underscores a heretofore previously unrecognized selectivity of the biochemical components that upstream from Ang I lead to cardiac Ang II production. The increased Ang-(1-12) expression and associated chymase gene transcript and activity is clinically relevant as AF is mainly a disease of the left atrium, a concept that agrees with the effectiveness of ablation techniques to interrupt aberrant electrical pathways in the left atria [Haissaguerre et al. 1998 ] and the association of AF with rare somatic mutations in left atrial myocytes [Gollob et al. 2006 ].
Conclusion
In summary, increased expression of the Ang-(1-12)/chymase pathway in the LAA of subjects undergoing cardiac surgery for correction of leftsided heart disease implicates these alternate mechanisms for tissue Ang II production in the processes accompanying adverse atrial and ventricular remodeling. The differential chymase and Ang-(1-12) expression in the atrial specimens provides an alternate rationale for the development of new therapeutic approaches to cardiac diseases. Our work has highly significant clinical implications because intracellular chymase-mediated Ang II formation is unaffected by ACE inhibitors or AT1 receptor antagonists, which act on the cell surface [Baker et al. 2004; Baker and Kumar, 2006 ].
Funding
Mehta, R., Supiano, M., Oral, H., Grossman, P., Petrusha, J., Montgomery, D. et al. (2000) Relation of systemic sympathetic nervous system activation to echocardiographic left ventricular size and performance and its implications in patients with mitral regurgitation. Am J Cardiol 86: 1193-1197.
Melendez, G., Li, J., Law, B., Janicki, J., Supowit, S. and Levick, S. (2011) Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. Cardiovasc Res 92: 420-429.
R E T R A C T E D
